VRTX is a biotechnology company that treats cystic fibrosis, influenza, bacterial infections, rheumatoid arthritis, cancer, inflammatory bowel disease, and neurological disorders including pain and multiple sclerosis. VRTX’s third-quarter fiscal 2027 report showed $3.44 billion in quarterly revenue (a 12% year-over-year gain) led by cystic fibrosis franchise growth as well as newer products like CASGEVY, JOURNAVX and PALSONIFY, non-GAAP per-share earnings of $4.76 (a 0.8% drop), adjusted operating income of $1.41 billion (a 2% rise), and raised full-year revenue guidance to a top end of $13.25 billion.
It’s no wonder VRTX shares are up 17% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the forward picture of the stock.
Institutions Buying Vertex Pharmaceuticals
Institutional volumes reveal plenty. In 2026, VRTX has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in VRTX shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Vertex Pharmaceuticals.
Vertex Pharmaceuticals Fundamental Analysis
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, VRTX has had strong sales and profits:
- 3-year sales growth rate (+11.3%)
- Profit margin (+32.7%)
Source: FactSet
Also, EPS is estimated to ramp higher this year by +10.6%.
Now it makes sense why the stock has been generating Big Money interest. VRTX has a track record of strong financial performance.
Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.
Vertex Pharmaceuticals has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s made the rare Outlier 20 inflow report 43 times since 2008, gaining 1,738%. The blue bars below show when VRTX was a top pick in the last five years…Big Money is a strong buyer:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Vertex Pharmaceuticals Price Prediction
The VRTX action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in VRTX at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.